Systems Biology of Drug Resistance and Metastasis in Breast Cancer

Tarih: 19.02.2016

Breast cancer is one of the most common cancers with >1,300,000 cases and 450,000 deaths each year worldwide. As most cancer-related deaths occur due to resistance to therapies and metastasis, it is crucial to elucidate the molecular mechanisms underlying these processes. In this respect, systems level approaches combined with cancer cell biology provide new avenues for targeting protein or non-coding RNA networks in an efficient way which may lead to blockage of by-pass mechanisms or metastasis spread of the cells.
In the first part of my seminar, I will present the development of combinatorial/sequential targeted therapies in trastuzumab (Herceptin) resistant breast cancer by modeling the disease using transgenic mouse models, analysis of signaling pathways and integrated patients’ data analysis. In the second part, I will talk about how a novel tumor suppressor miRNA simultaneously regulates both cell survival and epithelial mesenchymal transition (EMT) by regulating p53 expression and activity in a context-dependent manner whereby acting as a pleotropic therapy sensitizer in breast cancer.